LM Advisors LLC Invests $384,000 in GSK plc (NYSE:GSK)

LM Advisors LLC purchased a new stake in GSK plc (NYSE:GSKFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 10,361 shares of the pharmaceutical company’s stock, valued at approximately $384,000.

Several other large investors have also made changes to their positions in the company. Barometer Capital Management Inc. bought a new stake in GSK in the fourth quarter worth approximately $119,000. Neuberger Berman Group LLC increased its position in GSK by 5.7% in the 4th quarter. Neuberger Berman Group LLC now owns 32,435 shares of the pharmaceutical company’s stock worth $1,202,000 after buying an additional 1,763 shares during the period. Nomura Holdings Inc. lifted its holdings in shares of GSK by 40.0% during the fourth quarter. Nomura Holdings Inc. now owns 118,834 shares of the pharmaceutical company’s stock worth $4,404,000 after buying an additional 33,979 shares during the last quarter. Logan Capital Management Inc. boosted its position in shares of GSK by 3.8% in the fourth quarter. Logan Capital Management Inc. now owns 79,548 shares of the pharmaceutical company’s stock valued at $2,948,000 after acquiring an additional 2,897 shares during the period. Finally, Capital Fund Management S.A. increased its position in GSK by 100.7% during the fourth quarter. Capital Fund Management S.A. now owns 385,726 shares of the pharmaceutical company’s stock worth $14,295,000 after acquiring an additional 193,555 shares during the period. Institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. The Goldman Sachs Group initiated coverage on shares of GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price for the company. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Read Our Latest Research Report on GSK

GSK Price Performance

Shares of NYSE:GSK traded up $0.02 during midday trading on Wednesday, reaching $41.08. The company’s stock had a trading volume of 743,956 shares, compared to its average volume of 3,596,242. The business’s fifty day simple moving average is $42.57 and its 200-day simple moving average is $40.85. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The company has a market capitalization of $85.14 billion, a P/E ratio of 14.87, a P/E/G ratio of 1.25 and a beta of 0.66.

GSK (NYSE:GSKGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The firm had revenue of $9.34 billion during the quarter, compared to analysts’ expectations of $8.98 billion. As a group, equities research analysts expect that GSK plc will post 4.11 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a $0.3762 dividend. This represents a $1.50 dividend on an annualized basis and a yield of 3.66%. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is presently 53.26%.

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Further Reading

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.